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Background: We reported increased transmembrane TNF (tmTNF), but 
not the cleaved soluble TNF (sTNF), in the dorsolateral prefrontal cortex 
(DLPFC) from subjects with major depressive disorders (MDD)1 and have 
shown increased tmTNF in the anterior cingulate cortex (ACC), but not 
DLPFC, from subjects with bipolar disorder (BPD: data not shown). As 
TNF is predominantly expressed by neuroglia we have now measured the 
astrocytic marker, GFAP, to determine if there are generalised changes 
in astrocytic protein expression in MDD and BPD. Methods: Western 
blots were used to measure levels of GFAP in ACC from 10 subjects with 
BPD, 10 subjects with MDD and 10 age sex matched control subjects. 
Results: There were no significant changes in the intensities of any of 
the four GFAP immunogenic bands of molecular weights 37kDA (mean 
± SEM: BPD = 1.01 ± 0.52 vs. MDD = 1.17 ± 0.31 vs. Controls = 1.05 ± 
0.31 ratio internal control; p = 0.62), 41kDA (BPD = 0.74 ± 0.34 vs. MDD 
= 0.99 ± 0.33 vs. Controls = 1.06 ± 0.51; p = 0.24), 47kDA (BPD = 0.74 
± 0.60 vs. MDD = 1.33 ± 0.87 vs. Controls = 1.36 ± 0.81; p = 0.20) and 
50kDA (BPD = 2.02 ± 2.28 vs. MDD = 2.71 ± 1.96 vs. Controls = 2.73 ± 
2.14; p = 0.70) with diagnoses. Conclusions: Our data shows that levels 
of GFAP do not differ in ACC from subjects with mood disorders and 
suggest changes in tmTNF in that region in BPD are not associated with 
generalised changes in levels of astrocyte proteins. 1Dean B et al (In 
Press) J.Affect.Dis. 10.1016/j.jad.2009.04.027 [doi].
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Pro-inflammatory cytokines have been demonstrated to have a diverse 
range of actions on the functioning of the CNS, and in particular 
learning and memory behaviours. Details of the mechanisms of action 
of cytokines are still to be determined. Purpose: This study uses 
immunohistochemistry techniques (IHC) to investigate cellular changes 
present in the hippocampal formation as a result of up-regulation of 
astrocyte-produced tumour necrosis factor (TNF)α (GFAP-TNFα+/+), prior 
to onset of behavioural deficits. These findings are compared directly to 
the hippocampal formation of a TNFα knock-out model (TNFα-/-) in which 
marked alterations in learning and memory are observed at the same 
time-point (12 wks) and to age-match wild-type mice (WT). This time 
period is of critical importance for further elucidating the role of TNFα in 
hippocampal dependent learning and memory. Methods: Hippocampi 
from TNFα-/-, GFAP-TNFα+/+ and WT (n = 5) were subjected to indirect 
IHC for the analysis of TNFα levels and distribution in regions CA1, 
CA3 and the dentate gyrus (DG). Results: In GFAP-TNFα+/+ there was 
a demonstrated accumulation of TNFα in hippocampal neurons prior to 
the onset of hippocampal-dependent behavioural deficits. GFAP-TNFα+/+ 
mice also showed a significant increase in TNFα in regions CA3 and 
the DG (p = <0.05) when compared to WT and TNFα-/- mice. WT mice 
demonstrated immunoreactivity of TNFα in regions CA1 and the DG. 
Conclusion: These findings suggest that astrocyte-produced TNFα is 
essential for normal development and functioning of the CA1 region of 
the hippocampus in cognitive processes. However, an overproduction of 
astrocytic TNFα accumulates in the neurons of the CA3 and DG regions 
and likely produces functional deficits, as seen in 6 months plus mice, 
through these regions.
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Purpose: To investigate variability in outcomes and treatment response 
to antipsychotics as mediated by the perceived pharmacological action by 
the individual diagnosed with schizophrenia. Methods: A questionnaire 
consisting of subjective scales was sent to outpatients diagnosed with 
schizophrenia. The survey pack assessed the variables: symptom severity, 
medication side-effects, attitudes to treatment, quality of life (QoL), 
psychosocial function, neuro-cognitive deficits, coping skills, parental 
bonding and personality. Objective clinical measures of symptom severity, 
neuro-cognitive deficits and functioning were also examined and contrasted. 
A reliability test was used to assess internal consistency. Multivariate 
analysis of variance (MANOVA) was performed, with factors including 
antipsychotic-induced dysphoria and drug compliance, and dependent 
variables of symptoms, side effects, functioning and QoL. Multiple 
linear regression (MLR) was used to assess QoL and the contribution of 
symptoms, side effects, psychosocial functioning and treatment attitudes 
upon the QoL measures. Results: Reliability was upheld across the 
scales and subscales assessed within this sample population (n=242), with 
Cronbach’s alpha ranging from 0.6-0.9. MLR revealed 69% of variance in 
QoL was accounted by symptoms, side effects, treatment attitudes and by 
psychosocial functioning (p<0.01, n=242). Participants were further divided 
on the basis of subjective negativity towards treatment (ie: dysphoric vs 
non-dysphoric responses), where the subjectively negative participant 
appeared to have more severe symptoms, side-effects and a significantly 
reduced QoL (p<0.01), as did the non compliant participant. Conclusions: 
Subjective evaluation of antipsychotic action leads to differential treatment 
outcomes for symptoms, side effects and QoL. These results show that 
self-report measures can be quantified reliably and may provide unique 
insight into patients with schizophrenia. Such measures may be used to 
evaluate treatments, both pharmacological and non-pharmacological. This 
will allow for an assessment of broader outcomes than just symptomatic 
improvement, such as treatment attitudes and compliance, psychosocial 
functioning and quality of life.
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Background and Hypothesis: Schizophrenia (SCZ) is a complex 
neurological illness that affects 1% of the population. The molecular 
bases contributing to its pathology remain poorly understood. Genetic 
studies have linked NRG1 polymorphism to SCZ. Recent studies with 
mouse models have demonstrated that impaired NRG1-erbB signalling, 
due to knockout of BACE1 or of the gamma-secretase subunit, Aph1B 
gene leads to SCZ-like phenotypes that can be rescued by antipsychotics. 
We hypothesized that the expression of BACE1 and Aph1B, and the 
proteolytic processing of NRG1 may be altered in the prefrontal cortex 
of patients with SCZ. Methods: Samples from Brodmann 6 region (20 
SZ with normal levels of M1 muscarinic receptor; 20 SZ with low levels 
of M1 muscarinic receptor; 20 age-matched healthy controls - HC) were 
homogenized with TRIzol and the protein analysed by western blotting 
for BACE1, Aph1B and NRG-1. Band density was quantified relative 
to actin. Data were analysed with SPSS software using ANOVA and a 
significance p value of < 0.05. Results: Protein levels of BACE1, Aph1B, 
and NRG1 full-length did not differ significantly between the three groups. 
In contrast, ~ 50 % decrease in NRG-1 CTF was observed in both SCZ 
groups compared to the HC group (p < 0.001). There was a positive 
correlation between BACE1 and NRG-1 CTF n the HC group, but not 
in the SCZ groups. Conclusions: Our data suggest that the proteolytic 
processing of NRG-1 is impaired in SCZ. The molecular mechanisms 
that underlie the decrease in NRG-1 CTF remain to be elucidated.
